Tissue ELISA and Serum Amperometric Magnetoimmunosensor of ECD-HER2 In Stratifying Subtyping of Egyptian Woman Breast Cancers
Nakhla, S., Elwafe, Z., Saad, A., Aref, T., Ragab, N., elbadry, I., Eletxigerra, U., Campuzano, S., Martínez-Perdiguero, J., Merino, S., M. Pingarrón, J., Abdelmoneim, S., El-Abd, E. (2022). Tissue ELISA and Serum Amperometric Magnetoimmunosensor of ECD-HER2 In Stratifying Subtyping of Egyptian Woman Breast Cancers. EKB Journal Management System, (), -. doi: 10.21608/zumj.2022.161766.2643
Sameh Fawzy Nakhla; Zynab Elwafe; Ahmed Saad Saad; Tarek Aref; Noha Ragab; inas elbadry; Unai Eletxigerra Eletxigerra; Susana Campuzano; Jesus Martínez-Perdiguero; Santos Merino Merino; José M. Pingarrón; Salah Abdelmoneim; Eman El-Abd. "Tissue ELISA and Serum Amperometric Magnetoimmunosensor of ECD-HER2 In Stratifying Subtyping of Egyptian Woman Breast Cancers". EKB Journal Management System, , , 2022, -. doi: 10.21608/zumj.2022.161766.2643
Nakhla, S., Elwafe, Z., Saad, A., Aref, T., Ragab, N., elbadry, I., Eletxigerra, U., Campuzano, S., Martínez-Perdiguero, J., Merino, S., M. Pingarrón, J., Abdelmoneim, S., El-Abd, E. (2022). 'Tissue ELISA and Serum Amperometric Magnetoimmunosensor of ECD-HER2 In Stratifying Subtyping of Egyptian Woman Breast Cancers', EKB Journal Management System, (), pp. -. doi: 10.21608/zumj.2022.161766.2643
Nakhla, S., Elwafe, Z., Saad, A., Aref, T., Ragab, N., elbadry, I., Eletxigerra, U., Campuzano, S., Martínez-Perdiguero, J., Merino, S., M. Pingarrón, J., Abdelmoneim, S., El-Abd, E. Tissue ELISA and Serum Amperometric Magnetoimmunosensor of ECD-HER2 In Stratifying Subtyping of Egyptian Woman Breast Cancers. EKB Journal Management System, 2022; (): -. doi: 10.21608/zumj.2022.161766.2643

Tissue ELISA and Serum Amperometric Magnetoimmunosensor of ECD-HER2 In Stratifying Subtyping of Egyptian Woman Breast Cancers

Zagazig University Medical Journal
Articles in Press, Accepted Manuscript, Available Online from 05 October 2022  XML
Document Type: Original Article
DOI: 10.21608/zumj.2022.161766.2643
View on SCiNiTO View on SCiNiTO
Authors
Sameh Fawzy Nakhla email orcid 1; Zynab Elwafe2; Ahmed Saad Saad3; Tarek Aref4; Noha Ragab5; inas elbadry6; Unai Eletxigerra Eletxigerra7; Susana Campuzano8; Jesus Martínez-Perdiguero9; Santos Merino Merino7; José M. Pingarrón8; Salah Abdelmoneim10; Eman El-Abd1
1Radiation Sciences department, Medical Research Institute (MRI), Alexandria University, Alexandria, Egypt.
22. Radiology Department, Faculty of Medical Technology, Derna, Libya
3Experimental and Clinical Surgery Department, MRI, Alexandria University, Alexandria, Egypt.
4Radiodiagnosis Department, MRI, Alexandria University, Alexandria, Egypt.
5Department of Pathology, MRI, Alexandria University, Alexandria, Egypt
6Department of Cancer Management and Research, MRI, Alexandria University, Alexandria, Egypt
7Micro-NanoFabrication Unit, IK4-Tekniker, Eibar, Spain
8Departamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, Madrid, Spain.
9Universidad del País Vasco/Euskal Herriko Unibertsitatea, Bizkaia, Spain.
10Department of Clinical Oncology and Nuclear Medicine, faculty of medicine, AlexandriaUniversity, Alexandria, Egypt.
Abstract
Background: Detection of HER2 extracellular domain (ECD) amperometric magnetoimmunosensor (AM) investigated on raw cell lysates, intact breast cancer cells, and commercial and healthy sera except on patients' samples.
Aim: The current study aimed to validate tissue and serum AM of ECD-HER2 in subtyping Egyptian woman breast cancers and to compare it to the current techniques.
Subjects and Methods: We collected blood and tissues from 72 women (20 controls, five recurrent breast tumors, and 47 BCs). Tissue (tHER2) and serum HER2 (sHER2); are detected by ELISA and the AM. Results correlated with the clinicopathological parameters, and serum CA15-3 (sCA15-3).
Results: tHER2 (ELISA) and sCA15-3 significantly differed among the studied groups. tHER2 (ELISA) showed a significant decrease in higher BMI in the HER22+ group, while tHER2 and sHER2 (AM) significantly correlated in the HER23+ group. tHER2 (ELISA) significantly differed among BCs molecular subtypes. Both tHER2 and sHER2 (ELISA) significantly correlated in the HER2 molecular subgroup. sHER2 (AM) showed highly significant sensitivity and specificity in differentiating TN from luminal A at > 9.26 ng/ml and HER2 at 9.6 ng/ml. However, at > 1.67 ng/ml, tHER2 (ELISA) stratified significantly between BCs molecular and HER2 subgroups.
Conclusion: Tissue ELISA and serum AM provided accurate quantitative measurements for HER2 in various BC subtypes—at cut-off values lower than those approved by FDA—and would complement the current IHC and ISH techniques.
Keywords
Breast carcinoma, CA 15-3; HER2; immunoassay; immunosensors
Statistics
Article View: 1,106